|
[posting]61896638[/posting]Proteostasis Recruits Patients Quicker Than Anticipated, Results From CF Studies Now Expected Q4 2019 Nov. 12, 2019 2:58 PM ET Summary Proteostasis Therapeutics completes enrollment quicker than anticipated, now expects data from three 28-day phase 2 studies using doublet and triplet therapy for CF patients by Q4 2019. Company tumbled on phase 1 CF data for its doublet and triplet studies. However, changes to dosing/clinical trial design/longer treatment duration should achieve a better outcome in lung function improvement. The triplet therapy of PTI-801/PTI-808/PTI-428 is promising because, at day 14, there was no plateau in lung function improvement observed, which means efficacy could improve with more treatment days. Proteostasis has a major competitor to overcome, Vertex Pharmaceuticals, which has been a powerhouse in the CF space and had recently received FDA approval for its triplet therapy Trikafta.. https://seekingalpha.com/article/4305850-proteostasis-recrui… |
|
| aus der Diskussion: | Proteostasis Therapeutics ( PTI ) biopharmaceutical company |
| Autor (Datum des Eintrages): | bernie55 (25.11.19 10:22:58) |
| Beitrag: | 6 von 72 (ID:62004491) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |